

Vaxelis® (DTaP-HB-IPV-Hib)
Suspension for Intramuscular Injection
MA no. 66940

Active substances

Diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated), and *Haemophilus* type b conjugate vaccine (adsorbed).

Elements for a Public Summary -
Summary of the Safety Risk Management Plan (RMP)

Reference RMP EU RMP version 3.1, dated 25 February 2020

Products concerned (brand names): Vaxelis® (DTaP-HB-IPV-Hib)

Document status: Final

Data lock point (DLP) for this RMP: 3 October 2019

Document date: 25 February 2020

Marketing Authorization Holder
Future Health Pharma GmbH



CONTENTS

1	INTRODCUTION	3
I.	THE MEDICINE AND WHAT IT IS USED FOR.....	4
II.	RISKS ASSOCIATED WITH THE MEDICINE AND ACTIVITIES TO MINIMISE OR FURTHER CHARACTERISE THE RISKS.....	4
II.A	LIST OF IMPORTANT RISKS AND MISSING INFORMATION.....	5
2	TABLE II.A.1: LIST OF IMPORTANT RISKS AND MISSING INFORMATION	6
II.B	SUMMARY OF IMPORTANT RISKS.....	6
II.C	POST-AUTHORISATION DEVELOPMENT PLAN	6
II.C.1	STUDIES WHICH ARE CONDITIONS OF THE MARKETING AUTHORISATION.....	6
II.C.2	OTHER STUDIES IN POST-AUTHORISATION DEVELOPMENT PLAN	6



1 INTRODUCTION

The Risk Management Plan (RMP) is a comprehensive document submitted as part of the application dossier for market approval of a medicine. The RMP summary contains information on the medicine's safety profile and explains the measures that are taken in order to further investigate and follow the risks as well as to prevent or minimise them.

The RMP summary for “Vaxelis” is a concise document and does not claim to be exhaustive.

Please note that the reference document that is valid and relevant for the effective and safe use of “Vaxelis” in Switzerland is the “Arzneimittelinformation/ Information sur le médicament” (see www.swissmedic.ch) approved and authorised by Swissmedic. Future Health Pharma GmbH is fully responsible for the accuracy and correctness of the content of the published RMP summary for “Vaxelis”.

As the RMP is an international document, the summary might differ from the “Arzneimittelinformation / Information sur le médicament” approved and published in Switzerland, eg, by mentioning risks occurring in populations or indications not included in the Swiss marketing authorisation.



Summary of risk management plan for VAXELIS® Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate (Meningococcal Outer Membrane Protein Complex), and Hepatitis B (Recombinant) Vaccine adsorbed (DTaP-HB-IPV-Hib).

This is a summary of the risk management plan (RMP) for VAXELIS® (DTaP-HB-IPV-Hib). The RMP details important risks of VAXELIS® (DTaP-HB-IPV-Hib) and how more information will be obtained about VAXELIS® (DTaP-HB-IPV-Hib) risks and uncertainties (missing information).

VAXELIS® (DTaP-HB-IPV-Hib) summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how VAXELIS® (DTaP-HB-IPV-Hib) should be used.

This summary of the RMP for VAXELIS® (DTaP-HB-IPV-Hib) should be read in the context of all this information including the assessment report of the evaluation and its plain-language summary, all which is part of the European Public Assessment Report (EPAR).

Important new concerns or changes to the current ones will be included in updates of VAXELIS® (DTaP-HB-IPV-Hib) RMP.

I. THE MEDICINE AND WHAT IT IS USED FOR

VAXELIS® (DTaP-HB-IPV-Hib) is authorised for primary and booster vaccination in infants and toddlers from the age of 6 weeks, against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and invasive diseases caused by *Haemophilus influenzae* type b (Hib). It contains diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and *Haemophilus influenzae* type b conjugate vaccine (adsorbed) as the active substance and it is given by intramuscular administration.

Further information about the evaluation of VAXELIS® (DTaP-HB-IPV-Hib) benefits can be found in VAXELIS® (DTaP-HB-IPV-Hib) EPAR, including in its plain-language summary, available on the EMA website, under the medicine's webpage: <https://www.ema.europa.eu/en/medicines/human/EPAR/vaxelis>.

II. RISKS ASSOCIATED WITH THE MEDICINE AND ACTIVITIES TO MINIMISE OR FURTHER CHARACTERISE THE RISKS

Important risks of VAXELIS® (DTaP-HB-IPV-Hib), together with measures to minimise such risks and the proposed studies for learning more about VAXELIS® (DTaP-HB-IPV-Hib) risks, are outlined below.



Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute *routine risk minimisation* measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed, including PSUR assessment so that immediate action can be taken as necessary. These measures constitute *routine pharmacovigilance activities*.

II.A LIST OF IMPORTANT RISKS AND MISSING INFORMATION

Important risks of VAXELIS® (DTaP-HB-IPV-Hib) are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely administered. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of VAXELIS® (DTaP-HB-IPV-Hib). Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine);

Based on scientific information to date and the latest guidance on Risk Management Planning from the EMA, the Potential Risks and the Missing Information have been removed:

The risks are fully characterized and appropriately managed through labeling.

There is no reasonable expectation that any pharmacovigilance activity can further characterize the previously listed Potential risks and Missing Information.



2 TABLE II.A.1: LIST OF IMPORTANT RISKS AND MISSING INFORMATION

List of Important Risks and Missing Information	
Important identified risks	None
Important potential risks	None
Missing information	None

II.B SUMMARY OF IMPORTANT RISKS

The safety information in the proposed Prescribing Information is aligned to the reference medicinal product. There are no identified risks, potential risks, or missing information in this RMP.

II.C POST-AUTHORISATION DEVELOPMENT PLAN

II.C.1 STUDIES WHICH ARE CONDITIONS OF THE MARKETING AUTHORISATION

There are no studies which are conditions of the marketing authorisation or specific obligation of VAXELIS® (DTaP-HB-IPV-Hib).

II.C.2 OTHER STUDIES IN POST-AUTHORISATION DEVELOPMENT PLAN

There are no studies required for VAXELIS® (DTaP-HB-IPV-Hib).